Glioblastoma is the most aggressive malignant tumor of the central nervous system with a
low survival rate. The difficulty of obtaining this tumor material represents a major limitation …

In recent years, the classification of adult-type diffuse gliomas has undergone a revolution,
wherein specific molecular features now represent defining diagnostic criteria of IDH-wild …

Diffuse IDH-mutant astrocytoma mostly occurs in adults and carries a favorable prognosis
compared to IDH-wildtype malignant gliomas. Acquired mismatch repair deficiency is known …

Introduction: Pembrolizumab demonstrated promising results in hypermutated tumors of
diverse origin. Immunohistochemical loss of mismatch repair (MMR) proteins has been …

WHO 2016 classified glioblastomas into IDH-mutant and IDH-wildtype with the former
having a better prognosis but there was no study on IDH-mutant primary glioblastomas only …

Simple Summary Glioblastoma (GBM) is the most common and aggressive adult-type
diffusely infiltrating glioma. These tumors invariably develop resistance to standard …

Background: DNA mismatch repair (MMR) is a system for repairing errors in DNA replication.
Cancer cells with MMR deficiency can have immunohistochemical loss of MMR protein …

In 2017 the FDA (US Food and Drug Administration) approved pembrolizumab, a
programmed death 1 (PD-1) inhibitor, for the treatment of unresectable or metastatic …

Giant cell glioblastoma (GC-GBM) is a rare variant of IDH-wt GBM histologically
characterized by the presence of numerous multinucleated giant cells and molecularly …

Novel tissue-agnostic therapeutics targeting driver mutations in tumor cells have been
recently approved by FDA, driven by basket trials that have demonstrated their efficacy and …